5G

Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting

Chief Editor December 9, 2016 0 13 sec read
announced it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimer’s disease (AD), today at the 9 [th] Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Diego. Data presentations include interim results from the titration….

Posted: 2016-12-09 00:44:00

Read all

Chief Editor

View More Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Ntel announces Ernest Akinlola as new CEO

The board of ntel, Nigeria’s first 4G/LTE-Advanced network, has appointed Ernest Akinlola as its substantive Managing Director/Chief Executive Officer. Ernest is a senior executive with […]

October 8, 2017 0 12 sec read

Nearly 3.19 million 5G base stations in China by September

China had built 3.189 million 5G base stations by the end of September in its push to propel the digital and intelligent transformation of the […]

October 21, 2023 0 37 sec read

Canonical offers scalable mobile Android apps in the cloud

Canonical believes the ability to offload compute, storage and energy-intensive applications from devices (x86 and ARM) to the cloud enables users to consume advanced workloads […]

January 23, 2020 0 12 sec read

Reliance LYF Wind 5 launched at Rs. 6,599: How does it stack up against Meizu m2, Coolpad Note 3 Lite?

Reliance is on a handset launching spree as it unveiled yet another LYF smartphone — Wind 5 — in India, heating up competition in the […]

June 9, 2016 0 14 sec read